|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000128610 |
Summary for FEZF1 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000128610 | Gene symbol | FEZF1 |
| Gene name | FEZ family zinc finger 1 | |
| HGNC | 22788 | |
| Entrez ID | 389549 | |
| Gene type | protein_coding | |
| Synonyms | FEZF1| | |
| UniProtAcc | A0PJY2 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for FEZF1 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| FEZF1 | 1.05e+02 | 8.45e+00 | 1.29e+00 | 6.57e+00 | 4.97e-11 | 1.47e-09 | READ |
Top |
Sex-biased somatic mutation for FEZF1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for FEZF1 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| GBM | cg10385382 | chr7:122311001 | CGI:chr7:122310195-122310873 | promoter | 5.10e-01 | 3.87e-01 | 2.06e+00 | 3.98e-02 | 4.60e-02 | 1.23e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg02852327 | chr7:122310921 | CGI:chr7:122310195-122310873 | promoter | 3.85e-01 | 2.69e-01 | 2.47e+00 | 1.36e-02 | 1.72e-02 | 1.15e-01 |
| HNSC | cg13210470 | chr7:122310144 | CGI:chr7:122310195-122310873 | promoter,gene body | 2.18e-01 | 8.28e-02 | 5.06e+00 | 4.28e-07 | 2.95e-06 | 1.35e-01 |
| HNSC | cg02852327 | chr7:122310921 | CGI:chr7:122310195-122310873 | promoter | 4.10e-01 | 2.85e-01 | 3.09e+00 | 2.03e-03 | 3.31e-03 | 1.24e-01 |
| HNSC | cg10385382 | chr7:122311001 | CGI:chr7:122310195-122310873 | promoter | 2.61e-01 | 1.40e-01 | 2.72e+00 | 6.54e-03 | 8.93e-03 | 1.21e-01 |
| LUSC | cg13210470 | chr7:122310144 | CGI:chr7:122310195-122310873 | promoter,gene body | 2.87e-01 | 5.66e-02 | 4.35e+00 | 1.38e-05 | 5.26e-04 | 2.31e-01 |
| LUSC | cg20329153 | chr7:122310228 | CGI:chr7:122310195-122310873 | UTR,promoter,exon,gene body | 4.39e-01 | 2.99e-02 | 4.18e+00 | 2.94e-05 | 5.26e-04 | 4.09e-01 |
| LUSC | cg26769720 | chr7:122310452 | CGI:chr7:122310195-122310873 | UTR,promoter,exon,gene body | 3.66e-01 | 3.98e-02 | 3.66e+00 | 2.48e-04 | 1.09e-03 | 3.26e-01 |
| LUSC | cg01201519 | chr7:122310375 | CGI:chr7:122310195-122310873 | UTR,promoter,exon,gene body | 3.97e-01 | 1.69e-01 | 3.35e+00 | 7.97e-04 | 2.24e-03 | 2.28e-01 |
| LUSC | cg20183094 | chr7:122310870 | CGI:chr7:122310195-122310873 | promoter | 4.61e-01 | 2.40e-01 | 3.44e+00 | 5.75e-04 | 1.81e-03 | 2.21e-01 |
| LUSC | cg08004278 | chr7:122310872 | CGI:chr7:122310195-122310873 | promoter | 4.89e-01 | 2.18e-01 | 3.53e+00 | 4.11e-04 | 1.47e-03 | 2.70e-01 |
| LUSC | cg02852327 | chr7:122310921 | CGI:chr7:122310195-122310873 | promoter | 4.66e-01 | 2.85e-01 | 2.49e+00 | 1.29e-02 | 1.69e-02 | 1.81e-01 |
| LUSC | cg10385382 | chr7:122311001 | CGI:chr7:122310195-122310873 | promoter | 3.22e-01 | 1.35e-01 | 2.66e+00 | 7.78e-03 | 1.14e-02 | 1.87e-01 |
| CHOL | cg20329153 | chr7:122310228 | CGI:chr7:122310195-122310873 | UTR,promoter,exon,gene body | 2.97e-01 | 3.19e-02 | 2.58e+00 | 9.87e-03 | 2.15e-02 | 2.65e-01 |
| CHOL | cg20183094 | chr7:122310870 | CGI:chr7:122310195-122310873 | promoter | 5.29e-01 | 2.26e-01 | 3.54e+00 | 4.02e-04 | 8.32e-03 | 3.03e-01 |
| CHOL | cg08004278 | chr7:122310872 | CGI:chr7:122310195-122310873 | promoter | 5.82e-01 | 2.22e-01 | 3.54e+00 | 4.02e-04 | 8.32e-03 | 3.60e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg20329153 | chr7:122310228 | CGI:chr7:122310195-122310873 | UTR,promoter,exon,gene body | 2.99e-01 | 3.92e-02 | 1.10e+01 | 2.79e-28 | 3.32e-27 | 2.60e-01 |
| BRCA | cg26769720 | chr7:122310452 | CGI:chr7:122310195-122310873 | UTR,promoter,exon,gene body | 1.95e-01 | 3.11e-02 | 1.11e+01 | 1.78e-28 | 2.17e-27 | 1.64e-01 |
| BRCA | cg01201519 | chr7:122310375 | CGI:chr7:122310195-122310873 | UTR,promoter,exon,gene body | 3.98e-01 | 1.47e-01 | 1.20e+01 | 4.68e-33 | 1.02e-31 | 2.51e-01 |
| BRCA | cg20183094 | chr7:122310870 | CGI:chr7:122310195-122310873 | promoter | 4.72e-01 | 2.90e-01 | 1.09e+01 | 7.20e-28 | 8.18e-27 | 1.82e-01 |
| BRCA | cg08004278 | chr7:122310872 | CGI:chr7:122310195-122310873 | promoter | 4.98e-01 | 2.85e-01 | 1.10e+01 | 4.06e-28 | 4.74e-27 | 2.13e-01 |
| LIHC | cg20183094 | chr7:122310870 | CGI:chr7:122310195-122310873 | promoter | 4.00e-01 | 2.34e-01 | 3.64e+00 | 2.74e-04 | 8.30e-04 | 1.66e-01 |
| LIHC | cg02852327 | chr7:122310921 | CGI:chr7:122310195-122310873 | promoter | 5.32e-01 | 3.87e-01 | 3.58e+00 | 3.49e-04 | 9.99e-04 | 1.45e-01 |
Top |
Exon skipping events with PSI in TCGA for FEZF1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for FEZF1 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for FEZF1 |
| TFs related to FEZF1. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| FEZF1 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
 |
Top |
Sex-biased RBP-ES network for FEZF1 |
| RBPs related to ES in FEZF1. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| FEZF1 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs77361802 | chr7:118892742:C:T | - | 0.170650750252772 | 0.0278530648953972 | SARC | Female-baised eQTL |
| rs4728071 | chr7:127546395:T:C | - | -0.123033880699879 | 0.0277543697010445 | LUSC | Female-baised eQTL |
| rs2709501 | chr7:115008199:G:A | - | -0.182174413024733 | 0.0118674647310881 | STAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000128610 |
| CpG Site: cg23920642 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.201836921729265 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg23920642 | chr7:122307371 | gene | -0.201836921729265 | 1.4307185850054e-14 | -0.5115423300639856 | 2.087688027825495e-18 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of FEZF1 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000128610 | FEZF1 | C0342384 | Idiopathic hypogonadotropic hypogonadism | 1 | CTD_human |
| ENSG00000128610 | FEZF1 | C4014988 | HYPOGONADOTROPIC HYPOGONADISM 22 WITH OR WITHOUT ANOSMIA | 1 | CTD_human |
